Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases
Early detection of mucopolysaccharidosis (MPS) is an important factor in treatment success; therefore, good disease biomarkers are vital. We evaluate heparin cofactor II-thrombin complex (HCII-T) as a biomarker in serum and dried blood spots (DBS) of MPS patients. Serum HCII-T and urine dermatan sulphate:chondroitin sulphate (DS:CS) ratio are also compared longitudinally against clinical outcomes in MPSI, II and VI patients following treatment. Samples were collected from MPS patients at the Royal Manchester Children’s Hospital. DS:CS ratio was obtained by measuring the area density of spots from 2D electrophoresis of urinary glycosaminoglycans. Serum and DBS HCII-T was measured by sandwich ELISA. Serum HCII-T is elevated approximately 25-fold in MPS diseases that store DS, clearly distinguishing untreated MPSI, II and VI patients from unaffected age-matched controls. Serum HCII-T is also elevated in MPSIII, which leads to storage of heparan sulphate, with an increase of approximately 4-fold over unaffected age-matched controls. Urine DS:CS ratio and serum HCII-T decrease in response to treatment of MPSI, II and VI patients. HCII-T appears to respond rapidly to perturbations in treatment, whilst DS:CS ratio responds more slowly. HCII-T is a suitable biomarker for MPSI, II and VI, and it may also be informative for MPS diseases storing HS alone, such as MPSIII, although the elevation observed is smaller. In treated MPS patients, HCII-T and DS:CS ratio appear to measure short-term and long-term treatment outcomes, respectively. The potential value of HCII-T measurement in DBS for newborn screening of MPS diseases warrants further investigation.
- Boelens, J. J., Rocha, V., Aldenhoven, M., et al. (2009). Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant, 15(5), 618–625. CrossRef
- Canal MM, Wilkinson FL, Cooper JD, Wraith JE, Wynn R, Bigger BW (2010) Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB. Behav Brain Res 209(2): 212-20.
- Church, H., Tylee, K., Cooper, A., et al. (2007). Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant, 39(4), 207–210. CrossRef
- Decker, C., Yu, Z. F., Giugliani, R., et al. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med, 3(2), 89–100.
- Escolar, M. L., Poe, M. D., Provenzale, J. M., et al. (2005). Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med, 352(20), 2069–2081. CrossRef
- Harmatz, P., Giugliani, R., Schwartz, I. V., et al. (2008). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab, 94(4), 469–475. CrossRef
- Jones, S. A., Almassy, Z., Beck, M., et al. (2009). Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis, 32(4), 534–543. CrossRef
- Krivit, W. (2002). Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr, 49, 359–378.
- Krivit, W., Pierpont, M. E., Ayaz, K., et al. (1984). Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med, 311(25), 1606–1611. CrossRef
- Langford-Smith, K., Arasaradnam, M., Wraith, J. E., Wynn, R., & Bigger, B. W. (2010). Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Mol Genet Metab, 99(3), 269–274. CrossRef
- Malinowska, M., Wilkinson, F. L., Bennett, W., et al. (2009). Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab, 98(3), 235–242. CrossRef
- Matzner, U., Matthes, F., Weigelt, C., et al. (2008). Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease. J Mol Med, 86(4), 433–442. CrossRef
- Meikle, P. J., & Hopwood, J. J. (2003). Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr, 162(Suppl 1), S34–S37. CrossRef
- Meyer, A., Kossow, K., Gal, A., et al. (2007). Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics, 120(5), e1255–e1261. CrossRef
- Montano, A. M., Tomatsu, S., Gottesman, G. S., Smith, M., & Orii, T. (2007). International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis, 30(2), 165–174. CrossRef
- Peters, C., Shapiro, E. G., Anderson, J., et al. (1998). Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood, 91(7), 2601–2608.
- Peters, C., & Steward, C. G. (2003). Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant, 31(4), 229–239. CrossRef
- Randall, D. R., Colobong, K. E., Hemmelgarn, H., et al. (2008). Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab, 94(4), 456–461. CrossRef
- Randall, D. R., Sinclair, G. B., Colobong, K. E., Hetty, E., & Clarke, L. A. (2006). Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab, 88(3), 235–243. CrossRef
- Vellodi, A., Young, E. P., Cooper, A., et al. (1997). Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child, 76(2), 92–99. CrossRef
- Wraith, J. E. (2008). Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatr Suppl, 97(457), 76–78. CrossRef
- Wraith, J. E., Clarke, L. A., Beck, M., et al. (2004). Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr, 144(5), 581–588. CrossRef
- Wynn, R. F., Wraith, J. E., Mercer, J., et al. (2009). Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr, 154(4), 609–611. CrossRef
- Yamada, Y., Kato, K., Sukegawa, K., et al. (1998). Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant, 21(6), 629–634. CrossRef
- Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of Inherited Metabolic Disease
Volume 34, Issue 2 , pp 499-508
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. MPS Stem Cell Research Group, Faculty of Medical and Human Sciences, University of Manchester, 3.721 Stopford Building, Manchester, M13 9PT, UK
- 2. Genetic Medicine, St. Mary’s Hospital, Manchester, UK
- 3. Blood and Marrow Transplant Unit, Royal Manchester Children’s Hospital, Manchester, UK